Tech Company Financing Transactions
Artcline Funding Round
On 3/25/2024, Artcline announced $4.8 million in funding from private investors.
Transaction Overview
Company Name
Announced On
3/25/2024
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$4,750,000
Round
Undisclosed
Investors
Proceeds Purpose
With the additional funds, Artcline will finance the further execution of the randomized, controlled clinical trial ReActIF-ICE with more than 100 patients with septic shock.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Schillingallee 68
Rostock, 18057
Germany
Rostock, 18057
Germany
Phone
Website
Email Address
Overview
ARTCLINE's vision is to become the leading biotech company for immune cell based extracorporeal sepsis therapy. Currently, we are focused on the clinical trials and the further development of our ARTICE® Therapy for the treatment of bacterial sepsis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jens Altrichter
Chief Financial Officer
John Peitschner
Chief Scientific Officer
Steffen Mitzner
Browse more venture capital transactions:
Prev: 3/25/2024: Buddywise venture capital transaction
Next: 3/25/2024: Foundational venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. VC transactions reported here come from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs